论文部分内容阅读
目的探讨急性冠脉综合征(ACS)患者应用阿托伐他汀20mg/d;治疗的有效性和安全性。方法 97例ACS患者随机单盲分为2组,随访6个月,观察调脂疗效、药物不良反应及心脑血管缺血事件的发生情况。结果①治疗后总胆固醇(Tc)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和载脂蛋白B(APO-B)比治疗前均有明显降低,差异具有统计学意义(P<0.05);②高敏C反应蛋白(hs-CRP):阿托伐他汀治疗前、出院时及随访3、6个月hs-CRP水平可显著快速降低,各组间比较均P<0.05;③用药后未见与药物有关的肝肾损害、肌肉溶解及致残的严重不良反应。结论 ACS应用阿托伐他汀治疗能减少心脑血管缺血事件的发生,且安全、耐受性好,值得临床推广应用。
Objective To investigate the efficacy and safety of atorvastatin 20 mg / d in patients with acute coronary syndrome (ACS). Methods A total of 97 ACS patients were randomly divided into two groups. The patients were followed up for 6 months to observe the effects of lipid-lowering therapy, adverse drug reactions and cardiovascular and cerebrovascular ischemic events. Results ① The levels of total cholesterol (Tc), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein B (APO-B) were significantly lower than those before treatment (P <0.05) .②high-sensitivity C-reactive protein (hs-CRP): The levels of hs-CRP in atorvastatin before and at discharge and at 3 and 6 months of follow-up were significantly decreased ; ③ no drug-related liver and kidney damage, serious dissolution and disability of muscle after treatment. Conclusions ACS treatment with atorvastatin can reduce the incidence of cardiovascular and ischemic events, and is safe and well tolerated, which is worthy of clinical application.